These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 11278214

  • 1. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
    Tavaniotou A, Albano C, Smitz J, Devroey P.
    Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
    [Abstract] [Full Text] [Related]

  • 2. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G, Crosignani PG.
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [Abstract] [Full Text] [Related]

  • 3. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.
    Albano C, Smitz J, Tournaye H, Riethmüller-Winzen H, Van Steirteghem A, Devroey P.
    Hum Reprod; 1999 Jun; 14(6):1426-30. PubMed ID: 10357952
    [Abstract] [Full Text] [Related]

  • 4. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 5. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
    Bildik G, Akin N, Seyhan A, Esmaeilian Y, Yakin K, Keles I, Balaban B, Ata B, Urman B, Oktem O.
    Hum Reprod; 2019 Feb 01; 34(2):345-355. PubMed ID: 30520979
    [Abstract] [Full Text] [Related]

  • 6. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan 01; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 7. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C, Olivennes F, Righini C, Fanchin R, Taïeb J, Hamamah S, Bouchard P, Frydman R.
    Hum Reprod; 1999 Mar 01; 14(3):683-8. PubMed ID: 10221695
    [Abstract] [Full Text] [Related]

  • 8. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix.
    Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P.
    Fertil Steril; 1998 Aug 01; 70(2):357-9. PubMed ID: 9696235
    [Abstract] [Full Text] [Related]

  • 9. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P.
    Fertil Steril; 2013 Sep 01; 100(3):742-7. PubMed ID: 23806846
    [Abstract] [Full Text] [Related]

  • 10. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG, Bourgain C, Kolibianakis E, Tournaye H, Devroey P.
    Hum Reprod; 2005 Jun 01; 20(6):1541-7. PubMed ID: 15705618
    [Abstract] [Full Text] [Related]

  • 11. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, Diedrich K, Felberbaum R.
    Hum Reprod; 2005 May 01; 20(5):1200-6. PubMed ID: 15665010
    [Abstract] [Full Text] [Related]

  • 12. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, Thomsen L, Humaidan P.
    Hum Reprod; 2015 Oct 01; 30(10):2387-95. PubMed ID: 26209535
    [Abstract] [Full Text] [Related]

  • 13. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L, Tournaye H, Stoop D, Van Vaerenbergh I, Bourgain C, Polyzos NP, Haentjens P, Blockeel C.
    Reprod Biomed Online; 2014 Mar 01; 28(3):359-68. PubMed ID: 24456700
    [Abstract] [Full Text] [Related]

  • 14. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist.
    Tavaniotou A, Albano C, Smitz J, Devroey P.
    Fertil Steril; 2002 Apr 01; 77(4):733-7. PubMed ID: 11937125
    [Abstract] [Full Text] [Related]

  • 15. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility.
    Felberbaum RE, Reissmann T, Küpker W, Bauer O, al Hasani S, Diedrich C, Diedrich K.
    Eur J Obstet Gynecol Reprod Biol; 1995 Aug 01; 61(2):151-5. PubMed ID: 7556837
    [Abstract] [Full Text] [Related]

  • 16. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
    Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem A, Devroey P.
    Fertil Steril; 1997 May 01; 67(5):917-22. PubMed ID: 9130900
    [Abstract] [Full Text] [Related]

  • 17. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
    Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K, Devroey P.
    Hum Reprod; 2000 Mar 01; 15(3):526-31. PubMed ID: 10686191
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles.
    Norman RJ, Warnes GM, Wang X, Kirby CA, Matthews CD.
    Hum Reprod; 1991 Feb 01; 6(2):206-13. PubMed ID: 1905309
    [Abstract] [Full Text] [Related]

  • 19. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM, Nestor JJ, Vickery BH.
    Endocrinology; 1987 Aug 01; 121(2):612-8. PubMed ID: 3109885
    [Abstract] [Full Text] [Related]

  • 20. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
    Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ, Huang SC, Chen CY, Chen PH, Tzeng CR.
    Hum Reprod; 2004 Sep 01; 19(9):1993-2000. PubMed ID: 15284212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.